The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity - Baumgartner, Christina K.; Ebrahimi-Nik, Hakimeh; Iracheta-Vellve, Arvin; Hamel, Keith M.; Olander, Kira E.; Davis, Thomas G. R.; McGuire, Kathleen A.; Halvorsen, Geoff T.; Avila, Omar I.; Patel, Chirag H.; Kim, Sarah Y.; Kammula, Ashwin V.; et al. (Nature (London), 2023)
Keywords: 101/58; 13/1; 13/106; 13/21; 13/31; 13/51; 14; 14/34; 38/39; 38/91; 42/41; 59/5; 60 APPLIED LIFE SCIENCES; 631/67/1059/2325; 631/67/580; 64/60; 692/308/2778; 96/1; 96/31; Animal models; Animals; Antibodies; Antigens; Bioavailability; Cancer; Cancer immunotherapy; CD8 antigen; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - immunology; Cell culture; Cell growth; Clonal deletion; Design; Disease Models, Animal; Drug dosages; Drug Resistance, Neoplasm; Humanities and Social Sciences; Humans; Immune Checkpoint Inhibitors; Immune system; Immunity; Immunotherapy; Immunotherapy - methods; Inhibitors; Interferons - immunology; Killer Cells, Natural - drug effects; Killer Cells, Natural - immunology; Kinases; Lymphocytes; Lymphocytes T; Mice; multidisciplinary; Naphthalenes - pharmacology; Natural killer cells; Neoplasms - drug therapy; Neoplasms - enzymology; Neoplasms - immunology; Patients; PD-1 protein; Phosphatase; Phosphorylation; Plasma; preclinical research; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 2 - antagonists & inhibitors; Proteins; PTPN2 protein; Science; Science (multidisciplinary); Signal transduction; Solid tumors; T cell receptors; Therapeutic targets; Thiadiazoles - pharmacology; Tumor microenvironment; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; Tumors; tumour immunology; Tyrosine